Financial Performance - The company's operating revenue for Q3 2021 was ¥152,487,333.59, a decrease of 1.63% compared to the same period last year, while year-to-date revenue increased by 19.73% to ¥396,422,129.81[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,230,327.97, down 15.12% year-on-year, with a year-to-date net profit of ¥49,344,309.41, reflecting an 18.68% decrease[3] - The basic earnings per share for Q3 2021 was ¥0.20, a decline of 16.67% compared to the same period last year, with year-to-date earnings per share at ¥0.82, down 18.81%[3] - The net profit for Q3 2021 was CNY 47,286,377.81, a decrease of 19.5% compared to CNY 58,792,608.79 in Q3 2020[19] - The total profit for the period was CNY 53,319,278.12, down from CNY 66,781,382.09, reflecting a decline of 20.2% year-over-year[19] - Basic and diluted earnings per share were both CNY 0.82, compared to CNY 1.01 in the same quarter last year, indicating a decrease of 18.8%[20] - The total comprehensive income attributable to the parent company was CNY 49,344,309.41, down from CNY 60,680,371.19, reflecting a decline of 18.7%[20] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥881,801,697.35, representing a significant increase of 137.68% compared to the end of the previous year[3] - Total assets as of September 30, 2021, were ¥881,801,697.35, compared to ¥371,006,145.17 at the end of 2020, indicating a growth of 137.5%[17] - The company's total liabilities decreased to ¥111,741,881.49 from ¥130,282,379.57, a reduction of 14.1%[16] - The company's total liabilities stood at CNY 130,282,379.57, with non-current liabilities including lease liabilities of CNY 1,967,645.99[28] - Shareholders' equity totaled CNY 240,723,765.60, with retained earnings of CNY 116,373,429.76[28] - The equity attributable to shareholders increased to ¥773,754,983.52 from ¥242,361,001.66, reflecting a growth of 219.5%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥39,546,864.33, an increase of 12.60%[3] - Cash flow from operating activities generated a net amount of CNY 39,546,864.33, an increase of 12.3% from CNY 35,120,925.99 in the previous year[21] - Cash and cash equivalents increased significantly to ¥637,379,375.20 from ¥104,491,944.61, representing a growth of 510.5%[14] - Cash and cash equivalents at the end of the period totaled CNY 637,379,375.20, significantly up from CNY 80,425,679.46 at the end of the same quarter last year[23] - The company reported cash inflow from financing activities of CNY 537,803,960.00, a substantial increase compared to CNY 41,080,000.00 in the previous year[23] - The cash outflow for investment activities was CNY 3,993,603.56, a decrease from CNY 49,659,358.80 in the same period last year, indicating a reduction in investment spending[23] - The company experienced a net increase in cash and cash equivalents of CNY 532,887,430.59 during the period, compared to a decrease of CNY 15,163,804.57 in the previous year[23] Inventory and Costs - The company experienced a 50.81% decrease in inventory compared to the beginning of the year, mainly due to reduced stock of injectable cefotaxime sodium[8] - Inventory levels decreased to ¥7,294,220.05 from ¥14,827,808.31, a decline of 50.8%, suggesting improved inventory management[15] - Total operating costs amounted to ¥346,559,133.52, up 19.3% from ¥290,473,683.25 year-on-year[17] Research and Development - Research and development expenses for the period were ¥17,360,705.80, slightly up from ¥16,420,025.30, indicating a focus on innovation[17] Accounting and Standards - The company has implemented new leasing standards affecting the financial statements, indicating a shift in accounting practices[24] - The company adopted the new lease accounting standard, resulting in an increase of CNY 1,967,645.99 in both right-of-use assets and lease liabilities[29] - The third quarter report was not audited, indicating preliminary financial data[29] Market Strategy - The company aims to expand its market presence and enhance product offerings, although specific details on new products or technologies were not disclosed in the report[17] - The company has not disclosed any new product developments or market expansion strategies in the current report[28]
多瑞医药(301075) - 2021 Q3 - 季度财报